GenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH Tests

med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, and GenomOncology announce the expansion of med fusion’s LungSEQ® and 50SEQ® Plus FISH (for NSCLC) laboratory services to include PD-L1 expression testing. The panels will now help guide treatment selection of immunotherapeutic checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC). Read More